Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lorusso

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) groupS Pignata, G Scambia, C Pisano, et al.
Biochemical Pharmacology|August 8, 2017
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoproteinE Erba, M Romano, M Gobbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2012
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cellsShahriar Koochekpour, Sunipa Majumdar, Gissou Azabdaftari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialD Lorusso, G Scambia, S Pignata, et al.
ESMO Open|July 16, 2022
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447]S Ochsenreither, W M Fiedler, G Del Conte, et al.
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 8, 2017
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network settingI Ray-Coquard, AnnaLisa Trama, M J Seckl, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 14, 2026
Particle Beam Re-irradiation in Oligo Recurrent Gynecological MalignanciesA Barcellini, A Vai, G Fontana, et al.
Gynecologic Oncology|November 4, 2019
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trialD Lorusso, G Ferrandina, N Colombo, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) groupS Pignata, G Scambia, C Pisano, et al.
Biochemical Pharmacology|August 8, 2017
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoproteinE Erba, M Romano, M Gobbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2012
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cellsShahriar Koochekpour, Sunipa Majumdar, Gissou Azabdaftari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialD Lorusso, G Scambia, S Pignata, et al.
ESMO Open|July 16, 2022
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447]S Ochsenreither, W M Fiedler, G Del Conte, et al.
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 8, 2017
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network settingI Ray-Coquard, AnnaLisa Trama, M J Seckl, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 14, 2026
Particle Beam Re-irradiation in Oligo Recurrent Gynecological MalignanciesA Barcellini, A Vai, G Fontana, et al.
Gynecologic Oncology|November 4, 2019
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trialD Lorusso, G Ferrandina, N Colombo, et al.
Pageof 16